Skip to main content

Table 3 Clinical variables according to the presence or absence of anti-annexin V at baseline

From: Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study

Variable Anti-annexin V IgG p value Anti-annexin V IgM p value
Positive
(n = 11)
Negative
(n = 59)
Positive
(n = 10)
Negative
(n = 60)
Age (years), mean ± SD 48.73 ± 11.30 46.42 ± 12.79 0.579 49.90 ± 15.55 46.27 ± 12.02 0.399
Gender (F/M), n (%) 10/1 55/4 0.586 9/1 56/4 0.549
RP duration before diagnosis (years), mean ± SD 3.09 ± 3.48 5.47 ± 6.48 0.241 3.80 ± 3.88 5.32 ± 6.45 0.475
Disease duration (years), mean ± SD 9.18 ± 4.29 9.46 ± 6.59 0.894 10.00 ± 7.38 9.32 ± 6.12 0.752
Cutaneous subset (Diffuse/Limited) 5/6 20/39 0.341 3/7 22/38 0.490
Modified Rodnan cutaneous score 17.91 ± 13.05 12.22 ± 9.89 0.101 11.80 ± 9.77 13.33 ± 10.74 0.674
Calcinosis, n (%) 3 (27.3) 8 (13.6) 0.232 2 (20.0) 9 (15.0) 0.493
Telangiectasia, n (%) 5 (45.5) 33 (55.9) 0.261 6 (60.0) 32 (53.3) 0.655
Puffy fingers, (%) 1 (9.1) 12 (20.3) 0.345 0 (0.0) 13 (21.7) 0.109
Active digital ulcers, n (%) 3 (27.3) 11 (18.6) 0.382 1 (10.0) 13 (21.7) 0.357
Recurrent digital ulcers, n (%) 4 (36.4) 11 (18.6) 0.177 1 (10.0) 14 (23.3) 0.314
Necrosis or amputation of extremities, n (%) 3 (27.3) 1 (1.7) 0.011 1 (10.0) 3 (5.0) 0.232
Arthritis, n (%) 4 (36.4) 16 (27.1) 0.385 3 (30.0) 17 (28.3) 0.591
Esophageal involvement, n (%) 10 (90.9) 43 (72.9) 0.188 9 (90.0) 44 (73.3) 0.239
FVC < 70% predicted, n (%) 6 (54.5) 13 (22.0) 0.036 3 (30.0) 16 (26.7) 0.548
Interstitial lung involvement on CT scan, n (%) 8 (72.7) 28 (47.5) 0.112 7 (70.0) 29 (48.3) 0.177
PAH, n (%) 3 (27.3) 4 (6.8) 0.048 3 (30.0) 4 (6.7) 0.036
Diastolic dysfunction, n (%) 5 (45.5) 12 (20.3) 0.085 3 (30.0) 14 (23.3) 0.457
Renal crisis, n (%) 0 (0.0) 3 (5.1) 0.594 0 (0.0) 3 (5.0) 0.625
Raynaud Condition Score 6.00 ± 2.12 5.07 ± 2.27 0.002 5.18 ± 2.44 5.09 ± 2.29 0.873
HAQ-DI (score 0–3) 1.17 ± 0.55 0.70 ± 0.49 0.006 0.73 ± 0.58 0.78 ± 0.52 0.777
ACA, n (%) 5 (45.5) 23 (38.9) 0.688 6 (60.0) 22 (36.7) 0.163
Anti-Scl-70, n (%) 5 (45.5) 16 (27.1) 0.223 3 (30.0) 18 (30.0) 1.000
Anti-RNA polymerase III, n (%) 0 (0.0) 5 (8.5) 0.316 0 (0.0) 5 (8.3) 0.343
Nailfold videocapillaroscopy
 Number of capillaries/mm 7.14 ± 1.03 7.35 ± 1.00 0.513 7.09 ± 0.89 7.36 ± 1.02 0.429
 Enlarged capillaries 1.40 ± 0.73 1.0 ± 0.79 0.198 1.32 ± 0.57 1.08 ± 0.82 0.367
 Giant capillaries 0.24 ± 0.23 0.21 ± 0.24 0.728 0.29 ± 0.21 0.21 ± 0.24 0.313
 Microhemorrhages 0.56 ± 0.46 0.66 ± 0.63 0.624 1.0 ± 0.93 0.58 ± 0.51 0.192
 Avascular score 1.16 ± 0.59 0.93 ± 0.74 0.330 1.23 ± 0.66 0.92 ± 0.72 0.218
  1. Results are presented as mean ± standard deviation or absolute number and frequency